Practice
Featured experience
Evergy $1.2 billion at-the-market offering
We advised the forward counterparties on the offering
CoreWeave $2.6 billion convertible senior notes offering
We advised CoreWeave on the offering
Kroger $5 billion accelerated share repurchase
Kroger will receive an initial delivery of approximately 65.6 million shares
PPL $1.15 billion equity units offering
We advised PPL on the transaction
Davis Polk Advises Morgan Stanley on Its $3 Billion Senior Notes Offering
Davis Polk advised Morgan Stanley in connection with its SEC-registered global offering of $3 billion aggregate principal…
Intercept Pharmaceuticals, Inc. $460 Million Convertible Senior Notes Offering
Davis Polk acted as special product counsel to the representatives of the initial purchasers in connection with an SEC…
Universal American Corp. $115 Million Convertible Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Universal American Corp. of an…
Par Pacific Holdings $100 Million Convertible Senior Notes Offering
Davis Polk advised the representative of the initial purchasers in a Rule 144A offering by Par Pacific Holdings, Inc. of …
Nevro Corp. $172.5 Million Convertible Senior Notes Offering
Davis Polk advised the representatives of the several underwriters, in connection with an SEC-registered offering by Nevro…
The Medicines Company $402.5 Million Convertible Senior Notes Offering
Davis Polk advised the joint bookrunners in connection with a Rule 144A offering by The Medicines Company of $402.5 million…
TimkenSteel Corporation $75 Million Convertible Senior Notes Offering
Davis Polk advised the representative of the underwriters in connection with an SEC-registered offering by TimkenSteel…
Anacor $5.2 billion acquisition by Pfizer
Davis Polk is advising Anacor Pharmaceuticals, Inc. on its approximately $5.2 billion acquisition by Pfizer Inc. The…
Knowles Corporation $150 Million Convertible Senior Notes Offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Knowles…
Theravance Biopharma, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with a $115.1 million SEC-registered offering of 5,479,750…